SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SPRY is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key trend levels, sentiment has weakened after a payer coverage setback, and there is no Intellectia buy signal to support an aggressive entry. Even though analysts remain constructive and hedge funds are accumulating, the current setup favors waiting rather than buying immediately.
The current price is 8.44, below the pivot level of 9.126 and closer to support at 7.839 than resistance at 10.413. Momentum is weak: MACD histogram is -0.21 and still below zero, RSI_6 is 45.09, which is neutral but not bullish, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock trend model also points lower, with a 70% chance of declines over the next day, week, and month. This is a weak technical setup for a long-term beginner entry.
["Cantor Fitzgerald raised its price target to $30 from $12 and kept an Overweight rating.", "Northland initiated coverage with an Outperform rating and $25 price target.", "Hedge funds are buying, with buying activity up 326% over the last quarter.", "The long-term thesis around Neffy and future ARS-2 growth remains intact according to analysts."]
["Neffy did not receive new payer coverage, triggering a sharp 23% after-hours drop on 2026-06-24.", "Legal-related headlines followed the decline, which can keep sentiment pressured.", "Technical trend is bearish with MACD negative, weak RSI, and bearish moving averages.", "No AI Stock Picker signal and no SwingMax signal are present today.", "The modeled near-term stock trend is negative across the next day, week, and month."]
No latest-quarter financial snapshot was provided, so quarter-over-quarter revenue or earnings growth cannot be assessed. The available data does not include the latest quarter season, so there is no financial momentum confirmation for the stock from reported results.
Analyst sentiment is positive overall and has improved recently. On 2026-05-28, Cantor Fitzgerald raised its price target to $30 from $12 and kept an Overweight rating, highlighting long-term upside from neffy and potential future contribution from ARS-2. On 2026-04-09, Northland initiated coverage with an Outperform rating and a $25 target, also citing neffy adoption as the key growth driver. Wall Street’s pros view is that the company has a differentiated product and meaningful future pipeline upside; the cons view is that payer coverage, commercialization execution, and near-term adoption remain uncertain.
